171 related articles for article (PubMed ID: 29654782)
1. Mirabegron, a β
Mendes-Silvério CB; Alexandre EM; Lescano CH; Antunes E; Mónica FZ
Eur J Pharmacol; 2018 Jun; 829():79-84. PubMed ID: 29654782
[TBL] [Abstract][Full Text] [Related]
2. Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade.
Alexandre EC; Kiguti LR; Calmasini FB; Silva FH; da Silva KP; Ferreira R; Ribeiro CA; Mónica FZ; Pupo AS; Antunes E
Br J Pharmacol; 2016 Feb; 173(3):415-28. PubMed ID: 26493129
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Sasamata M
Naunyn Schmiedebergs Arch Pharmacol; 2013 Mar; 386(3):247-53. PubMed ID: 23239087
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the combination of KPR-5714, a novel transient receptor potential melastatin 8 (TRPM8) antagonist, and β
Aizawa N; Fujimori Y; Nakanishi O; Hayashi T; Goi Y; Kobayashi JI; Fujita T
Eur J Pharmacol; 2021 May; 899():173995. PubMed ID: 33675781
[TBL] [Abstract][Full Text] [Related]
5. Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response.
de Oliveira MG; Rojas-Moscoso JA; Bertollotto GM; Candido TZ; Kiguti LRA; Pupo AS; Antunes E; De Nucci G; Mónica FZ
Eur J Pharmacol; 2019 Sep; 858():172447. PubMed ID: 31228454
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Masuda N
Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):1001-8. PubMed ID: 23832377
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with the beta-3 adrenoceptor agonist, mirabegron ameliorates detrusor overactivity and restores cyclic adenosine monophosphate (cAMP) levels in obese mice.
Calmasini FB; de Oliveira MG; Alexandre EC; da Silva FH; da Silva CPV; Candido TZ; Antunes E; Mónica FZ
Neurourol Urodyn; 2017 Aug; 36(6):1511-1518. PubMed ID: 27794199
[TBL] [Abstract][Full Text] [Related]
8. Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction?
Gur S; Peak T; Yafi FA; Kadowitz PJ; Sikka SC; Hellstrom WJ
BJU Int; 2016 Sep; 118(3):464-74. PubMed ID: 27124860
[TBL] [Abstract][Full Text] [Related]
9. The metabolic effects of mirabegron are mediated primarily by β
Dehvari N; Sato M; Bokhari MH; Kalinovich A; Ham S; Gao J; Nguyen HTM; Whiting L; Mukaida S; Merlin J; Chia LY; Wootten D; Summers RJ; Evans BA; Bengtsson T; Hutchinson DS
Pharmacol Res Perspect; 2020 Oct; 8(5):e00643. PubMed ID: 32813332
[TBL] [Abstract][Full Text] [Related]
10. The β
Mo W; Michel MC; Lee XW; Kaumann AJ; Molenaar P
Br J Pharmacol; 2017 Aug; 174(16):2706-2715. PubMed ID: 28574581
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia.
Sawada N; Nomiya M; Hood B; Koslov D; Zarifpour M; Andersson KE
Eur Urol; 2013 Oct; 64(4):664-71. PubMed ID: 23838637
[TBL] [Abstract][Full Text] [Related]
12. The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?
Calmasini FB; Candido TZ; Alexandre EC; D'Ancona CA; Silva D; de Oliveira MA; De Nucci G; Antunes E; Mónica FZ
Prostate; 2015 Mar; 75(4):440-7. PubMed ID: 25417911
[TBL] [Abstract][Full Text] [Related]
13. Human β3-Adrenoreceptor is Resistant to Agonist-Induced Desensitization in Renal Epithelial Cells.
Milano S; Gerbino A; Schena G; Carmosino M; Svelto M; Procino G
Cell Physiol Biochem; 2018; 48(2):847-862. PubMed ID: 30032151
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cholinergic neurotransmission by β
Silva I; Costa AF; Moreira S; Ferreirinha F; Magalhães-Cardoso MT; Calejo I; Silva-Ramos M; Correia-de-Sá P
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F388-F403. PubMed ID: 28446460
[TBL] [Abstract][Full Text] [Related]
15. The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity.
Svalø J; Nordling J; Bouchelouche K; Andersson KE; Korstanje C; Bouchelouche P
Eur J Pharmacol; 2013 Jan; 699(1-3):101-5. PubMed ID: 23246623
[TBL] [Abstract][Full Text] [Related]
16. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
[TBL] [Abstract][Full Text] [Related]
17. Involvement of β3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: Direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor.
D' Agostino G; Maria Condino A; Calvi P
Eur J Pharmacol; 2015 Jul; 758():115-22. PubMed ID: 25861936
[TBL] [Abstract][Full Text] [Related]
18. Mirabegron: potential off target effects and uses beyond the bladder.
Dehvari N; da Silva Junior ED; Bengtsson T; Hutchinson DS
Br J Pharmacol; 2018 Nov; 175(21):4072-4082. PubMed ID: 29243229
[TBL] [Abstract][Full Text] [Related]
19. Beta-3 Adrenoceptor Signaling Pathways in Urothelial and Smooth Muscle Cells in the Presence of Succinate.
Mossa A; Velasquez Flores M; Nguyen H; Cammisotto PG; Campeau L
J Pharmacol Exp Ther; 2018 Nov; 367(2):252-259. PubMed ID: 30104323
[TBL] [Abstract][Full Text] [Related]
20. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.
Takusagawa S; Miyashita A; Iwatsubo T; Usui T
Xenobiotica; 2012 Dec; 42(12):1187-96. PubMed ID: 22834478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
